Featured Content


We're under way...

The ASCO '13 annual meeting abstracts were just released on Wednesday, and we're seeing a lot of media coverage. OBR covered the ASCO presscast the same day and is featured in a blog titled "ASCO '13: Studies Highlight Resource utilization, Immunotherapy, Targeted Therapy, and Physical Fitness".

Thomas, Marsland, MD
Vice President Integrated Community Oncology Network Former Community Representative ASCO Board of Directors

Doctors Should Discuss Financial Concerns of Cancer Patients

(DukeHealth.org) May 16, 2013 - Most cancer patients would like to talk about the cost of their care with their doctors, but often don't because they fear the discussion could compromise the quality of their treatment, researchers at Duke Cancer Institute report.

Commentary: Times certainly have changed. In the past our role as care givers was really only to discuss the effectiveness...

 1 comments  Add a comment
 facebook share button  twitter share button  linkedin share button



OBR Daily   Our free daily oncology focused e-news service.
Subscribe»  |  Search Archives»

Today's News

Novartis Drug Afinitor Significantly Extended Time Without Disease Progression in Women with HER2 Positive Advanced Breast Cancer

(Novartis) May 17, 2013 - Results of a pivotal Phase III trial in women with HER2 positive (HER2+) advanced breast cancer showed that Afinitor (everolimus) tablets in combination with trastuzumab (Herceptin) and vinorelbine significantly extended progression-free survival (PFS) after prior therapy when compared to treatment with placebo plus trastuzumab and vinorelbine, meeting the study's primary endpoint.
read corporate press release »

U.K. to Pilot Illumina Genetic Test for Breast, Ovarian Cancer

(Bloomberg) May 20, 2013 - The U.K. is piloting a new genetic test developed by Illumina Inc. to help cancer patients and their doctors better identify appropriate treatments and help determine if relatives have cancer risk.
read article »

MGH, AstraZeneca Partner to Create New Drug Combos

(Boston Globe) May 20, 2013 - Advances in genetic profiling have allowed doctors to match more of their cancer patients with treatments that will target their particular illnesses. But for some about one-third of cancer patients, there are no good matches, leaving them with only conventional chemotherapies and radiation.
read article (paid subscription required) »

 

View ALL News »




News Story Commentary By Academic and Community Oncologists



Doctors Should Discuss Financial Concerns of Cancer Patients (DukeHealth.org)

Times certainly have changed. In the past our role as care givers was really only to discuss the effectiveness...posted by: Thomas, Marsland, MD

Testicular Cancer Treatment May Not Require Radiation (Bloomberg)

Data from ASCO suggests that active surveillance is reasonable for Stage I seminomas after orchiectomy. Given the...posted by: Howard Sandler, MD, MS, FASTRO

Bayer, Algeta Win U.S. Approval for Prostate Cancer Drug (Bloomberg)

This is an important development, finally bringing an FDA approval to match with the overwhelming evidence supporting...posted by: H. Jack, West, MD

Oral Parity Update 2013: Federal Edition (ACCCBuzz)

Oral parity laws are becoming more common. The intent is to maintain access to care regardless of whether the...posted by: Thomas, Marsland, MD

Oral Parity Update 2013: Federal Edition (ACCCBuzz)

Just as an FYI, in most States, the oral parity regulations only apply to the fully insured groups, meaning small...posted by: Winston, Wong, PharmD






OBR Training


Learn more about the OBR training platform, developed to provide an in-depth understanding of the unique business dynamics of today's oncology landscape.




OBR Job Board

Novocure has posted 3 new jobs and Sarah Cannon has 1 job posted on the OBR Job Board.

View all job listings here


Intellisphere_Lung_300x250

The most comprehensive and up-to-date oncology pipeline information on the web!
OBR Pipeline Online™






View company profiles, indexes, and streaming stock quotes of over 200 oncology focused companies.

Winners/Losers

Symbol  %Δ
PFE +0.00%
ARIA +0.00%
MYGN +0.00%
PFE +0.00%
ARIA +0.00%
MYGN +0.00%


    


OBR Radar

View upcoming pivotal oncology events such as PDUFA dates, ODAC dates, and announcement of phase III clinical trial results


Date: June 3, 2013
Company: GlaxoSmithKline
Product: dabrafenib

Date: June 5, 2013
Company: Celgene Corp.
Product: Revlimid® (lenalidomide)

Date: July 15, 2013
Company: Boehringer Ingelheim Pharmaceuticals
Product: afatinib (BIBW 2992)

See All OBR Radar items»




OBR's Oncology Events Calendar is a compilation of important upcoming conferences and meetings that is updated daily.